Snap-8

In cosmetic chemistry Snap-8 goes by the name acetyl octapeptide-3 (also acetyl glutamyl octapeptide-3). The peptide is two amino acids longer at the C-terminus than acetyl hexapeptide-3, better known as Argireline, and was designed as its successor for dermatological research.

The point of attack is the SNARE complex. This protein scaffold makes vesicles fuse at the presynaptic membrane and release their neurotransmitter. In study models Snap-8 competes for a place in the complex and thereby slows the release of acetylcholine at neuromuscular synapses. From that follows the hypothesis that the tiny muscles beneath the skin receive fewer cholinergic signals and expression lines are dampened locally.

What the clinical data offer:

• For Argireline, not for Snap-8 itself: a 10 percent emulsion cut wrinkle depth by as much as 30 percent after 30 days.
• A randomized, placebo-controlled Argireline study with 60 participants found a subjectively rated anti-wrinkle effect of 48.9 percent after four weeks against 0 percent under placebo, plus lower measured skin roughness.
• In a study that used acetyl octapeptide-3 alongside other actives, microneedle patches made of hyaluronic acid trimmed fine lines by 25.8 percent over twelve weeks; what share the single peptide had in that remains open.

Some papers link the longer sequence to higher potency; overall, though, the data on Snap-8 are thinner than on Argireline, which has the longer research history. The peptide is studied topically, and systemic availability is low, which is why the research concentrates on local action in the skin.

Snap-8 is described as well tolerated in studies. Because it is examined topically and hardly enters the circulation, the observed effects stay local. What you should keep in mind:

• Skin: mild redness, dryness or irritation at the application site is the most common observation.
• Local action: in topical setups, inhibition of the SNARE complex affects only the treated area.
• Thin data: most clinical figures come from Argireline; Snap-8 itself is far less studied, and the only human work with the peptide combines it with other actives.
• Humans: robust human studies on Snap-8 alone and long-term data are missing.

This summary is no substitute for medical advice.

• A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells - mechanistic basis: a peptide modelled on the C-terminus of SNAP-25 blocks the docking of secretory vesicles in chromaffin cells.
• A synthetic hexapeptide (Argireline) with antiwrinkle activity - Argireline paper with up to 30 percent less wrinkle depth after 30 days under a 10 percent emulsion.
• The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study - randomized Argireline study with 60 participants, subjective effect 48.9 percent against 0 under placebo.
• Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study - microneedle patches with several peptides, among them acetyl octapeptide-3: 25.8 percent fewer fine lines in twelve weeks.